Secukinumab shows high efficacy irrespective of
            <i>HLA‐Cw6</i>
            status in patients with moderate‐to‐severe plaque‐type psoriasis: results from extension phase of the SUPREME study

Papini, Manuela; Cusano, Francesco; Romanelli, Marco; Burlando, Martina; Stinco, Giuseppe; Girolomoni, Giampiero; Peris, Ketty; Potenza, Concetta; Offidani, Annamaria; Bartezaghi, Marta; Aloisi, Elisabetta; Costanzo, Antonio; Bianchi, Luca; Bottoni, Ugo; Buligan, Cinzia; Brazzelli, Valeria; Campanati, Anna; Cantoresi, Franca; Capo, Alessandra; Cattaneo, Angelo; Dapavo, Paolo; Giglio, Micol Del; Lernia, Vito Di; Nuzzo, Sergio Di; Simone, Clara De; Dusi, Daniele; Fargnoli, Concetta; Flori, Laura; Franchi, C.; Galluzzo, Marco; Ghilardi, Alberto; Hansel, Katharina; Loconsole, Francesco; Lora, Viviana; Malagoli, Piergiorgio; Malara, Giovanna; Mastrandrea, Valentina; Megna, Matteo; Mercuri, Raffaele; Musumeci, Letizia; Naldi, Luigi; Narcisi, Alessandra; Orsini, Diego; Pagnanelli, Gianluca; Patrizi, Annalisa; Pau, Monica; Pellacani, Giovanni; Persechino, Severino; Piaserico, Stefano; Pietroleonardo, Lucia; Prignano, Francesca; Reseghetti, A.; Russo, Filomena; Sirna, Riccardo; Skroza, Nevena; Stingeni, Luca; Trevisini, Sara; Zane, Cristina; Zichichi, Leonardo; Zini, Antonio

doi:10.1111/bjd.18013

Cited by 23 publications

(27 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL‐17A, has shown good efficacy and safety in the treatment of both moderate‐severe psoriasis and PsA 12,19,22 . Additionally, it has been well demonstrated that it is highly effective regardless of HLA‐Cw6 so that the determination of HLA‐Cw6 status is not necessary to predict an extremely satisfying clinical outcome 23,24 . Secukinumab provides significant benefits in terms of clinical response, measured as reduction of PASI 75 and PASI 90, and in some patients complete skin clearance is achieved (PASI 100), which is the overall aim of treatment according to Italian guidelines 25 …”

Section: Discussionmentioning

confidence: 99%

“…12,19,22 Additionally, it has been well demonstrated that it is highly effective regardless of HLA-Cw6 so that the determination of HLA-Cw6 status is not necessary to predict an extremely satisfying clinical outcome. 23,24 Secukinumab provides significant benefits in terms of clinical response, measured as reduction of PASI 75 and PASI 90, and in some patients complete skin clearance is achieved (PASI 100), which is the overall aim of treatment according to Italian guidelines. 25 Secukinumab represents an important advance in treatment of psoriasis considering its efficacy and safety in populations with a range of comorbidities (including older patients and patients with PsA), its low immunogenic potential, and its effectiveness in difficultto-treat areas, such as the scalp, palmoplantar regions, legs, and nails.…”

Section: Efficacy and Safetymentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study

Carpentieri

Mascia

Fornaro

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

This study assessed the effectiveness and safety of secukinumab in patients with moderate-severe psoriasis vulgaris in a real-world setting. A total of 120 patients (35.8% women; mean age 49.8 years) were enrolled. Mean PASI significantly decreased from 12.0 ± 6.6 at baseline to 4.7 ± 3.2 and 2.3 ± 4.0 at 3 and 12 months, respectively (P < .001). Patients with two or more lines of prior biological therapies had poorer persistence to therapy at 12 months (71%) vs those who were bio-naïve (93%) or patients with only one prior failure with a biological agent (88%) (logrank = 9.33; P = .009). Multivariate regression analysis showed that patients beyond the second line of treatment had an increased risk of discontinuing secukinumab (HR: 3.6; 95% CI 1.3-10.2), while those without comorbidities had a lower risk (HR: 0.31; 95% CI 0.1-0.8). Our study confirms the effectiveness and safety of secukinumab in a real-life setting for psoriatic disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Efficacy and Safetymentioning

confidence: 99%

Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study

Carpentieri

Mascia

Fornaro

et al. 2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

“…Taken together, these results indicate that HLA-C*06:02 is not a good candidate marker for secukinumab therapy, as this treatment is highly effective regardless of the HLA-C*06:02 status [68]. An extension phase of the SUPREME study confirmed these results, establishing that secukinumab was equally effective in both HLA-C*06:02-positive and HLA-C*06:02-negative patients with PASI response rates comparable between both groups up to week 72 [69].…”

Section: Anti-il17 Drugsmentioning

confidence: 86%

Pharmacogenetics Update on Biologic Therapy in Psoriasis

et al. 2020

View full text Add to dashboard Cite

Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response. Materials and Methods: In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs. Results: Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele. Conclusions: Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.

show abstract

“…Other two SNPs cosegregating with HLA-Cw6, namely rs12189871 and rs4406273 showed the same pattern of presence in patients and, thus, identical regression curves Figure 1b. 100 (41) 85.0 (17) 88.5 (23) 84.8 (28) 89.2 (33) 85.4 (35) 88.3 (38) 95.3 (41) 57.9 (11) 66.7 (12) 54.5 (6) 58.3 (7) 68.8 (11) 64.7 (11) 57.9 (11) 63.2 (12) 68.4 (13) 23 (25) 87.8 (36) 70.0 (14) 69.2 (18) 72.7 (24) 83.8 (31) 80.5 (33) 81.4 (35) 86.0 (37) 42.1 (8) 55.6 (10) 36.4 (4) 50.0 (6) 62.5 (10) 58.8 (10) 52.6 (10) 52.6 (10) 52.6 ( (14) 70.7 (29) 50.0 (10) 42.3 (11) 51.5 (17) 62.2 (23) 63.4 (26) 69.7 (30) 67.4 (29) 21.1 433.3 (6) 27.3 333.3 …”

Section: Snps In Hla-c and Upstream Region Associate With Clinical Rementioning

confidence: 99%

“…42.9 (6) 57.1 (8) 71.4 (10) 81.3 (39) 95.7 (44) 81.8 (18) 85.2 (23) 83.8 (31) 87.8 (36) 86.9 (40) 87.5 (42) 91.7 36.4 (4) 50.0 (6) 53.8 (7) 42.9 (6) 35.7 (5) 50.0 (7) 58.3 (28) 84.8 (39) 68.2 (15) 74.1 (20) 75.7 (28) 82.9 (34) 80.4 (37) 83.3 (40) 83 31.3 (15) 65.2 (30) 50.0 (11) 48.1 (13) 59.5 (22) 68.3 (28) 67.4 (31) 70.8 (34) 62.5 Figure 2. Association analysis between rs9267325 SNP and clinical response to secukinumab.…”

Section: Hla-cw6 Status Identifies Specific Snp Patterns In Psoriaticmentioning

confidence: 99%

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

Morelli

Galluzzo

Madonna

et al. 2020

Expert Opinion on Biological Therapy

Self Cite

View full text Add to dashboard Cite

show abstract

Secukinumab shows high efficacy irrespective of HLA‐Cw6 status in patients with moderate‐to‐severe plaque‐type psoriasis: results from extension phase of the SUPREME study

Cited by 23 publications

References 7 publications

Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study

Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study

Pharmacogenetics Update on Biologic Therapy in Psoriasis

HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis

Contact Info

Product

Resources

About